EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Eikon Therapeutics, Inc. Common Stock
EIKN

EIKN Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. Common Stock · NASDAQ
Market Closed
8.94
▼ ⁦-2.93%⁩ (-0.27)
Market Cap$484.0M
Beta0.85
52w Low52w High
7.9017.40
Last Week
⁦-21.44%⁩
Last Month
⁦-8.12%⁩
Last 3 Months
⁦-17.15%⁩
Last Year
—
EL7 Factor Analysis
How we score this
Overall15
Poor — bottom quartile of the marketDistressBetter than 15% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
4
—17.8xBottom tier
▸
Growth
43
—7.1%Around median
▸
Quality
—
—4.5%N/A
▸
Safety
35
—2.6xBottom tier
▸
Capital Return
36
—2.12%Bottom tier
▸
Momentum
20
—2.9%Bottom tier
▸
Sentiment
91
5▲3Top tier

Frequently Asked Questions

What is Eikon Therapeutics, Inc. Common Stock stock?▼

Eikon Therapeutics, Inc. Common Stock is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in Eikon Therapeutics, Inc. Common Stock?▼

You can buy Eikon Therapeutics, Inc. Common Stock shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating Eikon Therapeutics, Inc. Common Stock?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does Eikon Therapeutics, Inc. Common Stock pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in Eikon Therapeutics, Inc. Common Stock?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.

Fair Value
Low confidenceCurrent price$8.94
Analyst target · 1 analysts
$5.00
⁦-44%⁩
See it clearly overvalued
Range ⁦$5.00–$5.00⁩
vs
DCF (estimate)
N/A (negative FCF)

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener

AI analysis from the earnings call, financials and news

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 1 analysts setting price target
$5.00
⁦-44.1%⁩
Current Price $8.94·Median $5.00
Low
$5.00
High
$5.00
Street summary

Eikon Therapeutics (EIKN) Price Target Analysis

Bearish tilt

Eikon Therapeutics stock shows a sharp divergence between its current market price (11.16) and the consensus price target of $5, indicating a negative outlook from analysts covering the price target. Targets have seen no change over the past thirty days, with only one analyst setting a price target, reflecting weak coverage or a state of high uncertainty regarding the stock's fair valuation in the absence of expected revenue until 2029.

As of 2026-08-24
Revisions momentum · 30d
⁦0.0%⁩
Average rating
★ 4.00
Buy
Analyst coverage
6
Buy conviction
83%
High
Rating activity · 30d
0↑ · 0↓
Target dispersion
0%
Analyst ratings over time6 analysts rating
2
3
1
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months4.00 → 4.00
Recent analyst moves
  • = Reiterate2026-08-21
    Cantor Fitzgerald
    Overweight
  • = Reiterate2026-08-14
    Wedbush
    Underperform
  • = Reiterate2026-06-02
    Cantor Fitzgerald
    Overweight
Premium content
Financial Analysis
|